JP2005509597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509597A5 JP2005509597A5 JP2003519439A JP2003519439A JP2005509597A5 JP 2005509597 A5 JP2005509597 A5 JP 2005509597A5 JP 2003519439 A JP2003519439 A JP 2003519439A JP 2003519439 A JP2003519439 A JP 2003519439A JP 2005509597 A5 JP2005509597 A5 JP 2005509597A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- 1racp
- composition according
- receptor
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims 7
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 7
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 6
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 2
- -1 IFNγ Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31078901P | 2001-08-07 | 2001-08-07 | |
| PCT/US2002/024948 WO2003014309A2 (en) | 2001-08-07 | 2002-08-07 | Interleukin-1 receptors in the treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509597A JP2005509597A (ja) | 2005-04-14 |
| JP2005509597A5 true JP2005509597A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
Family
ID=23204113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003519439A Pending JP2005509597A (ja) | 2001-08-07 | 2002-08-07 | 疾患の治療におけるインターロイキン−１受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030049255A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1450837A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005509597A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002324625B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2456762A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04001187A (cg-RX-API-DMAC7.html) |
| PL (1) | PL374118A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003014309A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL138930A0 (en) * | 1998-05-15 | 2001-11-25 | Genentech Inc | Il-17 homologies polypeptides and therapeutic uses thereof |
| US7771719B1 (en) * | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20090035261A1 (en) * | 2000-03-21 | 2009-02-05 | Jian Chen | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20030203451A1 (en) * | 2000-08-24 | 2003-10-30 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7718397B2 (en) * | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| US20030180255A1 (en) * | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20030096969A1 (en) * | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP3594228A1 (en) * | 2003-07-08 | 2020-01-15 | Genentech, Inc. | Il-17a/f heterologous polypedtides and therapeutic uses thereof |
| JP4875494B2 (ja) * | 2003-11-14 | 2012-02-15 | ユーシーエル バイオメディカ ピーエルシー | 免疫調節物質 |
| WO2005051422A1 (en) | 2003-11-21 | 2005-06-09 | Celltech R & D Limited | Method for the treatment of multiple sclerosis by inhibiting il-17 activity |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1751175B1 (en) * | 2004-05-05 | 2012-07-25 | VALORISATION-RECHERCHE, Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| JP2008542685A (ja) * | 2005-05-05 | 2008-11-27 | ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット | サイトカイン受容体修飾因子及びその使用 |
| WO2007050607A2 (en) | 2005-10-26 | 2007-05-03 | Novartis Ag | Novel use of il-1beta compounds |
| US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| JP2009183176A (ja) * | 2008-02-05 | 2009-08-20 | Univ Of Tokyo | Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス |
| AU2009245440C1 (en) | 2008-05-05 | 2013-03-14 | Novimmune Sa | Anti-IL-17A/IL-17F cross-reactive antibodies and methods of use thereof |
| KR20110028457A (ko) * | 2008-05-21 | 2011-03-18 | 뉴로테즈 인코포레이티드 | 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법 |
| AU2010244142B2 (en) * | 2009-05-05 | 2016-07-21 | Novimmune Sa | Anti-IL-17F antibodies and methods of use thereof |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| PT2582391T (pt) | 2010-06-18 | 2019-01-11 | Xbiotech Inc | Tratamento da artrite |
| CN103459424B (zh) | 2011-01-19 | 2017-11-10 | 坎塔吉亚有限责任公司 | 抗il1rap抗体及其治疗人类的用途 |
| US9724409B2 (en) * | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| CA2894219C (en) | 2012-12-10 | 2020-08-11 | Vib Vzw | Novel interleukin-33 inhibitors |
| US10906971B2 (en) | 2015-06-26 | 2021-02-02 | Sanofi Biotechnology SAS | Monoclonal anti-IL-1RAcP antibodies |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
| US11633425B2 (en) | 2021-05-13 | 2023-04-25 | Ahava—Dead Sea Laboratories Ltd. | Anti-glycation compositions |
| KR20250060305A (ko) | 2022-09-21 | 2025-05-07 | 사노피 바이오테크놀로지 | 인간화 항-il-1r3 항체 및 사용 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989004838A1 (en) * | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5350683A (en) * | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| AU651596B2 (en) * | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| CA2133326C (en) * | 1992-03-30 | 2005-03-01 | Craig A. Smith | Fusion proteins comprising tumor necrosis factor receptor |
| PE64396A1 (es) * | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| NZ322197A (en) * | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| DE69816109T2 (de) * | 1997-04-24 | 2004-04-22 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte imidazole zur behandlung von entzündlichen krankheiten |
| AU2001259758A1 (en) * | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
-
2002
- 2002-08-07 MX MXPA04001187A patent/MXPA04001187A/es not_active Application Discontinuation
- 2002-08-07 EP EP02759279A patent/EP1450837A4/en not_active Withdrawn
- 2002-08-07 JP JP2003519439A patent/JP2005509597A/ja active Pending
- 2002-08-07 WO PCT/US2002/024948 patent/WO2003014309A2/en not_active Ceased
- 2002-08-07 PL PL02374118A patent/PL374118A1/xx not_active Application Discontinuation
- 2002-08-07 AU AU2002324625A patent/AU2002324625B2/en not_active Ceased
- 2002-08-07 CA CA002456762A patent/CA2456762A1/en not_active Abandoned
- 2002-08-07 US US10/215,211 patent/US20030049255A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005509597A5 (cg-RX-API-DMAC7.html) | ||
| McCulloch et al. | Signalling platforms that modulate the inflammatory response: new targets for drug development | |
| Vane et al. | Inflammation and the mechanism of action of anti‐inflammatory drugs | |
| Mentink‐Kane et al. | Opposing roles for IL‐13 and IL‐13 receptor α2 in health and disease | |
| ES2659205T3 (es) | Uso de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il)piperidin-2,6-diona en el tratamiento de enfermedades inflamatorias y relacionadas con el sistema inmune | |
| US4871733A (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
| CN100519554C (zh) | 用於治疗爱滋病之ccr5拮抗剂 | |
| TW449473B (en) | Compositions for inhibition of the pathophysiologic actions in mammals of tumor necrosis factor-alpha | |
| JP2005533005A5 (cg-RX-API-DMAC7.html) | ||
| EP0321490B1 (en) | Inhibition of interleukin-1 production by monocytes and/or macrophages | |
| JPH06505497A (ja) | 血小板凝集阻害剤として有用なフェニルアミジン誘導体類 | |
| WO2004082715A1 (ja) | 炎症性腸疾患治療剤としての併用医薬 | |
| JP2002515400A (ja) | ある種のジアリールイミダゾール誘導体；新規なクラスのｎｐｙ特異的リガンド | |
| JP2003512429A (ja) | デスロラタジンを用いた睡眠障害処置 | |
| EP1450837A2 (en) | Interleukin-1 receptors in the treatment of diseases | |
| AU2002324625A1 (en) | Interleukin-1 receptors in the treatment of diseases | |
| KR20010102460A (ko) | 운동 유발 천식의 치료 방법 | |
| JP2013506696A5 (cg-RX-API-DMAC7.html) | ||
| Corwin et al. | Renal insufficiency associated with nonsteroidal anti-inflammatory agents | |
| Owen et al. | Methotrexate in Reiter's disease. | |
| Kudlacz et al. | Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule α4β1 antagonists | |
| JP2005526053A5 (cg-RX-API-DMAC7.html) | ||
| JP2002501039A (ja) | Ｖｌａ−４アンタゴニスト | |
| US20030176316A1 (en) | Methods for treatment of rheumatoid arthritis | |
| JP4139453B2 (ja) | 細胞接着阻害剤 |